KEY TAKEAWAYS
- The study aimed to investigate the role of CD247 and CD4 expression in TNBC prognosis.
- The results showed low CD247 and CD4 expression predicts poor outcomes in patients with TNBC.
Ankit Pateriya and the team aimed to evaluate the prognostic significance of CD247 and CD4 expression in triple-negative breast cancer (TNBC), an aggressive form of breast cancer with a poor prognosis. The tumor microenvironment of TNBC includes various cell types, such as tumor-infiltrating lymphocytes (TILs), which play a crucial role in cancer progression and resistance to chemotherapy.
Researchers used online computational tools to evaluate the prognostic significance of CD247 and CD4 expression in patients with TNBC. They analyzed the correlation between these markers and immune cell infiltration, including dendritic cells, B-cells, CD4+ cells, CD8+ cells, and neutrophils.
The results demonstrated that patients with TNBC having lower CD247 and CD4 expression had significantly shorter relapse-free survival and overall survival (OS) than those with higher expression levels. The expression of CD247 and CD4 showed a strong positive correlation with tumor-infiltrating dendritic cells, B-cells, CD4+, CD8+, and neutrophils.
The study concluded that low levels of CD247 and CD4 may impair immune cell infiltration in the tumor microenvironment, hindering cancer cell elimination and leading to poor patient outcomes. CD247 and CD4 could serve as useful biomarkers and potential therapeutic targets in TNBC.
No funding information was given.
Source: https://pubmed.ncbi.nlm.nih.gov/39342598/
Pateriya A, Nema R, Mishra AK, et al. (2024). “Decreased Expression of CD247 and CD4 Immune Marker Predicts Poor Prognosis in Triple Negative Breast Cancer.” Asian Pac J Cancer Prev. 2024;25(9):3187-3197. Published 2024 Sep 1. doi:10.31557/APJCP.2024.25.9.3187
